Australian-Singaporean regenerative medicine company Osteopore Limited – a global leader in 3D-printed biomimetic and bioresorbable implants – is delighted to announce the successful commencement of first-in-human clinical trials for knee preservation in Singapore. On 22 April 2024, the first patient was treated for knee preservation with Heparan Sulphate 3 (HS3) and aXOpore® via a High Tibial Osteotomy (HTO) at the National University Hospital (NUH), Singapore.
The commencement of first-in-human clinical trials comes on the back of the signing of two non-binding term sheets on 14 April 2023 with Accelerate Technologies Pte Ltd (A*STAR) to commercialise groundbreaking technology that accelerates bone and tissue regeneration.
Highlights
- First patient treated with Heparan Sulphate 3 (HS3) and aXOpore® via a High Tibial Osteotomy (HTO) at Singapore’s National University Hospital (NUH).
- Studies seek to recruit ~12 patients to establish a safety profile for aXOpore®, and to investigate the product’s efficacy in enhancing osteosynthesis in HTO patients.
- Targeting bone morphogenetic protein-2 (BMP-2), HS3 accelerates bone regeneration in patients undergoing knee preservation surgery via HTO.
- HS3 is being developed with the Institute of Molecular and Cell Biology (IMCB) under Singapore’s Agency for Science, Technology, and Research (A*STAR).
